{
    "pmid": "41445850",
    "title": "[",
    "abstract": "Immune checkpoint inhibitor treatment in non-small cell lung cancer (NSCLC) expands to early stages of disease. The neoadjuvant setting allows to investigate the mechanism-of-action of immune therapy using molecular imaging and tissue analysis. We investigated the safety and feasibility of programed cell death ligand-1 (PD-L1) PET-imaging with  This Phase I-II study (NCT03514719) enrolled 20 patients with Stage Ia-IIIa NSCLC who received two cycles of avelumab (10â€…mg/kg Q2W) prior to surgery. In the imaging optimization part, [ [ [",
    "disease": "lung cancer",
    "clean_text": "immune checkpoint inhibitor treatment in non small cell lung cancer nsclc expands to early stages of disease the neoadjuvant setting allows to investigate the mechanism of action of immune therapy using molecular imaging and tissue analysis we investigated the safety and feasibility of programed cell death ligand pd l pet imaging with this phase i ii study nct enrolled patients with stage ia iiia nsclc who received two cycles of avelumab mg kg q w prior to surgery in the imaging optimization part"
}